MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--An innovative medical device used in the minimally invasive treatment of thoracic aortic aneurysms, the Valiant® Thoracic Stent Graft System from Medtronic, Inc. (NYSE: MDT), delivered excellent clinical results through one year of patient follow-up in the company’s U.S. pivotal study, VALOR II, according to data presented today at a meeting for vascular surgeons.
